Syngene swings to Rs 9 cr loss as operating margin drops to 12.34%
Revenue fell 15.84% YoY while expenses declined 3.43%; a Rs 10.2 cr tax benefit softened the pre-tax loss.
Filed 29 Jul 2026, 17:36 IST · after market close · Syngene International Ltd (SYNGENE)
Key takeaways
- Syngene posted a consolidated net loss of Rs 9.0 cr in Q1FY27 as operating margin fell 16.93 percentage points QoQ to 12.34%.
- Revenue fell 15.84% YoY while expenses declined only 3.43%, driving operating profit down 56.01%.
- A Rs 10.2 cr tax benefit partly cushioned the Rs 19.2 cr pre-tax loss, leaving EPS at Rs -0.22.
Price around the results
Revenue contraction overwhelmed the cost base
Syngene's consolidated revenue fell 28.99% QoQ and 15.84% YoY, while operating profit dropped 70.07% QoQ and 56.01% YoY. The sequential decline was especially damaging because expenses fell only 11.99%, leaving the business with much lower operating leverage. Interest costs declined 20.66% QoQ, but that was not enough to offset the operating shortfall.
Margin fell below the healthcare peer median
Operating margin narrowed 16.93 percentage points QoQ and 11.26 percentage points YoY because expenses declined less than revenue. At 12.34%, Syngene's margin was 15.13 percentage points below the 27.47% median for 13 healthcare peers that had reported, ranking fourth from the bottom. Other income of Rs 11.8 cr did not prevent a pre-tax loss, while the Rs 10.2 cr tax benefit reduced the reported net loss from Rs 19.2 cr to Rs 9.0 cr.
Q4 margin rebound reversed in Q1FY27
The 12.34% margin reversed the improvement to 29.27% in Q4FY26 and remained below the 23.60% recorded in Q1FY26. The multi-quarter path has been uneven: margin declined from 23.60% in Q1FY26 to 21.91% in Q2FY26, recovered to 29.27% by Q4FY26, and then fell sharply in the latest quarter.
Management highlights facility expansion and execution changes
Management said Syngene acquired a multimodal biologics manufacturing facility from Stelis Biopharma. The company presentation said it is automating workflows to reduce errors and improve execution quality. It also said it is developing supply-chain resilience through dual sourcing and domestic supplier development for critical raw materials.
No immediate market reaction after the filing
The results were filed after market close, so there is no immediate market reaction to report. Across eight past result sessions, the stock rose four times and fell four times, with a median absolute move of 6.01%, indicating that the historical response has been evenly split but sizeable.
Q1FY27 at a glance
Consolidated figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹736 cr | ₹1,037 cr | -28.99% | -15.84% |
| Other income | ₹12 cr | ₹16 cr | -27.16% | -33.33% |
| Expenses | ₹645 cr | ₹733 cr | -11.99% | -3.43% |
| Operating profit | ₹91 cr | ₹303 cr | -70.07% | -56.01% |
| Operating margin (%) | 12.34% | 29.27% | — | — |
| Interest | ₹10 cr | ₹12 cr | -20.66% | -17.24% |
| Depreciation | ₹112 cr | ₹112 cr | +0.63% | +0.90% |
| Profit before tax | ₹-19 cr | ₹196 cr | — | — |
| Tax | ₹-10 cr | ₹48 cr | — | — |
| Net profit | ₹-9 cr | ₹148 cr | — | — |
| EPS (₹) | ₹-0.22 | ₹3.68 | — | — |
Operating margin of 12.34% compares with a Healthcare sector median of 27.47% across 13 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Expansion
- Syngene acquired a multimodal biologics manufacturing facility from Stelis Biopharma.
New initiatives
- Syngene is automating workflows to eliminate errors and improve execution quality.
- Syngene is developing a resilient supply chain through dual sourcing and domestic supplier development for critical raw materials.
Problems & risks
- Syngene identifies critical raw materials as an area requiring domestic supplier development.
What to watch
- Whether revenue recovers from Rs 736.0 cr without expenses again falling less than revenue.
- Whether operating margin improves from 12.34% toward the 27.47% healthcare-peer median.
- Whether net profit returns from a Rs 9.0 cr loss after the Rs 10.2 cr tax benefit.